<?xml version="1.0" encoding="UTF-8" standalone="no"?><?xml-stylesheet type="text/css" href="uslm.css"?><bill xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm https://www.govinfo.gov/schemas/xml/uslm/uslm-2.0.17.xsd">
<!--Disclaimer: Legislative measures that include compacts or other non-standard data structures will require additional modeling and may contain inconsistencies in the converted USLM XML.-->
<meta><dc:title>119 S 201 ENR: To provide for a study by the National Academies of Sciences, Engineering, and Medicine on the prevalence and mortality of cancer among individuals who served as active duty aircrew in the Armed Forces, and for other purposes.</dc:title>
<dc:type>Senate Bill</dc:type><docNumber>201</docNumber><citableAs>119 S 201 ENR</citableAs>
<citableAs>119s201enr</citableAs>
<citableAs>119 S. 201 ENR</citableAs>
<dc:creator>United States Senate</dc:creator><dc:publisher>United States Government Publishing Office</dc:publisher><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights><docStage>ENR</docStage>
<processedBy>GPO Locator to USLM Converter 4.12.3;Stage2.20240826</processedBy><processedDate>2025-07-21</processedDate>
<congress>119</congress><session>1</session><publicPrivate>public</publicPrivate>
</meta>
<preface><dc:type>S.</dc:type><docNumber>201</docNumber>

<congress style="-uslm-lc:I665502" value="119">One Hundred Nineteenth Congress of the United States of America</congress><session style="-uslm-lc:I665503" value="1">A T T  H  E F  I  R  S  T S  E  S  S  I  O  N</session>
<enrolledDateline style="-uslm-lc:I665504">Begun and held at the City of Washington on Friday, the third day of January, two thousand and twenty five</enrolledDateline>
</preface>
<main>
<longTitle>
<docTitle class="centered fontsize18" style="-uslm-lc:I665505">An Act</docTitle>
<officialTitle class="centered fontsize8" style="-uslm-lc:I665511">To provide for a study by the National Academies of Sciences, Engineering, and Medicine on the prevalence and mortality of cancer among individuals who served as active duty aircrew in the Armed Forces, and for other purposes.<?GPOvSpace 08?></officialTitle>
</longTitle>
<enactingFormula style="-uslm-lc:I650120"><i>  Be it enacted by the Senate and House of Representa­tives of the United States of America in Congress assembled,</i></enactingFormula>
<section id="d82e62" identifier="/us/bill/119/s/201/s1" style="-uslm-lc:I650146"><num class="bold" value="1">SECTION 1. </num><heading>SHORT TITLE.</heading><content style="-uslm-lc:I650120">  This Act may be cited as the “<shortTitle role="act">ACES Act of 2025</shortTitle>”.</content></section>
<section id="d82e72" identifier="/us/bill/119/s/201/s2" style="-uslm-lc:I650141"><num class="fontsize12" value="2">SEC. 2. </num><heading>NATIONAL ACADEMIES STUDY ON PREVALENCE AND MORTALITY OF CANCER AMONG INDIVIDUALS WHO SERVED AS ACTIVE DUTY AIRCREW IN THE ARMED FORCES.</heading><subsection class="firstIndent0 fontsize10" id="y275e8b50-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a" style="-uslm-lc:I650120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10 smallCaps">Agreement<inline class="noSmallCaps">.—</inline></heading><paragraph class="firstIndent0 fontsize10" id="y275eb261-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/1" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><heading class="fontsize10 smallCaps">In general<inline class="noSmallCaps">.—</inline></heading><content>Not later than 30 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall seek to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (in this section referred to as the “National Academies”), under which the National Academies shall conduct a study on the prevalence and mortality of cancers among covered individuals.</content></paragraph><paragraph class="firstIndent0 fontsize10" id="y275ed972-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/2" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><heading class="fontsize10 smallCaps">Deadline<inline class="noSmallCaps">.—</inline></heading><subparagraph class="firstIndent0 fontsize10" id="y275ed973-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/2/A" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><heading class="fontsize10 smallCaps">Date<inline class="noSmallCaps">.—</inline></heading><content>The Secretary shall finalize the agreement under paragraph (1) by not later than 60 days after the date on which the Secretary enters negotiations with the National Academies with respect to such agreement.</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275ed974-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/2/B" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><heading class="fontsize10 smallCaps">Report; briefings<inline class="noSmallCaps">.—</inline></heading><chapeau>If the Secretary fails to satisfy the requirement under subparagraph (A), the Secretary shall—</chapeau><clause class="firstIndent0 fontsize10" id="y275ed975-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/2/B/i" style="-uslm-lc:I650126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><chapeau>submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report that includes—</chapeau><subclause class="firstIndent0 fontsize10" id="y275ed976-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/2/B/i/I" style="-uslm-lc:I650128"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">(I) </num><content>an explanation of the reasons the Secretary failed to satisfy such requirement; and</content></subclause><subclause class="firstIndent0 fontsize10" id="y275ed977-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/2/B/i/II" style="-uslm-lc:I650128"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">(II) </num><content>an estimate of the date on which the Secretary will finalize the agreement under paragraph (1); and</content></subclause></clause><clause class="firstIndent0 fontsize10" id="y275ed978-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/a/2/B/ii" style="-uslm-lc:I650126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>not less frequently than once every 60 days after the date on which the Secretary failed to satisfy such requirement, provide to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a briefing on the progress of the Secretary toward finalizing such agreement.</content></clause></subparagraph></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y275ed979-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b" style="-uslm-lc:I650120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10 smallCaps">Study<inline class="noSmallCaps">.—</inline></heading><chapeau>The study required under subsection (a) shall—</chapeau><paragraph class="firstIndent0 fontsize10" id="y275ed97a-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/1" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>identify exposures associated with military occupations of covered individuals, including relating to chemicals, compounds, agents, and other phenomena;</content></paragraph><paragraph class="firstIndent0 fontsize10" id="y275f008b-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><chapeau>review the literature to determine associations between exposures referred to in paragraph (1) and the incidence or prevalence of overall cancer morbidity, overall cancer mortality, and increased incidence or prevalence of—</chapeau><subparagraph class="firstIndent0 fontsize10" id="y275f008c-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/A" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>brain cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f008d-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/B" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>colon and rectal cancers;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f008e-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/C" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><content>kidney cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f008f-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/D" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">(D) </num><content>lung cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f0090-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/E" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="E">(E) </num><content>melanoma skin cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f0091-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/F" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="F">(F) </num><content>non-Hodgkin lymphoma;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f0092-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/G" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="G">(G) </num><content>pancreatic cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f0093-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/H" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="H">(H) </num><content>prostate cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f0094-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/I" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">(I) </num><content>testicular cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f0095-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/J" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="J">(J) </num><content>thyroid cancer;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f0096-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/K" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="K">(K) </num><content>urinary bladder cancer; and</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f27a7-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/2/L" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="L">(L) </num><content>other cancers as determined appropriate by the Secretary of Veterans Affairs, in consultation with the National Academies; and</content></subparagraph></paragraph><paragraph class="firstIndent0 fontsize10" id="y275f27a8-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/3" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><chapeau>determine, to the extent possible, the prevalence of and mortality from the cancers specified in paragraph (2) among covered individuals by using available sources of data, which may include—</chapeau><subparagraph class="firstIndent0 fontsize10" id="y275f27a9-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/3/A" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>health care and other administrative databases of the Department of Veterans Affairs, the Department of Defense, and the individual Services, respectively;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f27aa-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/3/B" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>the national death index maintained by the National Center for Health Statistics of the Centers for Disease Control and Prevention; and</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y275f27ab-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/b/3/C" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><content>the study conducted under section 750 of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (<ref href="/us/pl/116/283">Public Law 116–283</ref>; <ref href="/us/stat/134/3716">134 Stat. 3716</ref>).</content></subparagraph></paragraph></subsection><subsection class="firstIndent0 fontsize10" id="y275f27ac-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/c" style="-uslm-lc:I650120"><num class="fontsize10" style="-uslm-lc:emspace2" value="c">(c) </num><heading class="fontsize10 smallCaps">Report<inline class="noSmallCaps">.—</inline></heading><content>At the conclusion of the study required under subsection (a), the National Academies shall submit to the Secretary, the Committee on Veterans’ Affairs of the Senate, and the Committee on Veterans’ Affairs of the House of Representatives a report containing the results of the study described in subsection (b).</content></subsection><subsection class="firstIndent0 fontsize10" id="y275f27ad-66b0-11f0-8b88-ddfae940159d" identifier="/us/bill/119/s/201/s2/d" role="definitions" style="-uslm-lc:I650120"><num class="fontsize10" style="-uslm-lc:emspace2" value="d">(d) </num><heading class="fontsize10 smallCaps">Covered Individual Defined<inline class="noSmallCaps">.—</inline></heading><content>In this section, the term “<term>covered individual</term>” means an individual who served on active duty in the Army, Navy, Air Force, or Marine Corps as an aircrew member of a fixed-wing aircraft, including as a pilot, navigator, weapons systems operator, aircraft system operator, or any other crew member who regularly flew in a fixed-wing aircraft.</content></subsection></section>
</main>
<signatures>
<signature><role style="-uslm-lc:I650114">Speaker of the House of Representatives.</role></signature>
<signature><role style="-uslm-lc:I650114">Vice President of the United States and  President of the Senate.</role></signature>
</signatures>
</bill>